PEOPLE


Poonam A. Arora

Investment Analyst and Co-Portfolio Manager

Poonam is an investment analyst and co-portfolio manager for Seamist Capital. She has more than 10 years of experience in equity research, having followed the biotechnology, pharmaceuticals, and medical technology sectors at the Stanford Group in Boston, and at Roth Capital Partners, Madison Williams, WR Hambrecht, and the Maxim Group in New York. During her tenure on the sell-side, she covered small-cap and large-cap healthcare companies based both in United States and Europe.

Poonam has served as stock advisor to sell-side analysts associated with Canaccord Genuity, Think Equity, Global Hunter Securities, and WBB Securities and buy-side analysts at hedge funds that will remain anonymous due to confidentiality agreements. She has significant experience in stock picking and trading in healthcare companies both as an analyst and individual investor.

Her claim to fame is her persistently accurate analysis of Puma Biotechnology, a stock she has a sell rating on since March 2014. She subsequently published 6 more sell rating articles on the stock even when shares were trading at roughly $280, and sell-side analysts had Price Targets of over $300/share. The company reached a bottom of ~$20/share and is now trading at ~$50/share. The analysis among others can be read on Seeking Alpha.

Poonam earned a masters in finance from Hofstra University in New York and a bachelors in business administration from Northern Arizona University in Flagstaff. In addition, she has earned credits in biotechnology and pharmaceutical related content from several Ivy League universities. Poonam has passed the Series 7, 63, 86, and 87 but is not currently registered. She publishes her views on healthcare stocks on Seeking Alpha. Poonam has been ranked as 22nd of over 4,100 financial bloggers by TipRanks for 2014.

Ranked 22nd of over 4,100 financial bloggers for 2014 -- TipRanks

Average return per recommendation of 35.6% for 2014 -- TipRanks

Seeking Alpha featured columnist on biotechnology companies